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LEE E. FARR LECTURE
Hormone resistance in diabetes and 
obesity: insulin, Leptin, and FGF21
Jeffrey S. Flier
Dean of the Faculty of Medicine, Harvard University, Harvard Medical School, Boston,
Massachusetts
This an edited transcript of the Lee E. Farr Lecture given by Dr. Jeffrey Flier on May 8, 2012,
at the culmination of the annual Student Research Day at the Yale School of Medicine. In
this presentation, Dr. Flier discusses his and his wife’s research on insulin, leptin, and FGF21
in the context of his reflections upon his life’s work and his advice for young investigators.
introduction
Dr. Jeffrey S. Flier was named the 21st
Dean of the Faculty of Medicine at Harvard
University on July 11, 2007. Flier, an en-
docrinologist and an authority on the mo-
lecular causes of obesity and diabetes, is
also the Caroline Shields Walker Professor
of Medicine at Harvard Medical School
(HMS). Previously, he served as HMS Fac-
ulty  Dean  for  Academic  Programs  and
Chief Academic  Officer  for  Beth  Israel
Deaconess  Medical  Center  (BIDMC),  a
Harvard teaching affiliate.
Flier was born in New York City. He
received a BS from City College of New
York in 1968 and an MD from Mount Sinai
School of Medicine in 1972, graduating
with the Elster Award for Highest Aca-
demic Standing. Following his residency
training in internal medicine at Mount Sinai
Hospital from 1972 to 1974, Flier moved
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a Clinical Associate. In 1978, he joined the
Faculty of Medicine at HMS, serving as
Chief of the Diabetes unit at Beth Israel
Hospital until 1990, when he was named
chief of the hospital’s Endocrine Division.
In 2002, Flier was named Chief Aca-
demic Officer of BIDMC, a newly created
senior position responsible for research and
academic programs. He worked with Beth
Israel  Deaconess  academic  department
chairs to ensure the quality and breadth of
academic programs at the Medical Center,
through which most of HMS students pass.
He also served as the formal liaison to HMS,
sitting on the Council of Academic Deans.
Flier is one of the country’s leading in-
vestigators in the areas of obesity and dia-
betes.  His  research  has  produced  major
insights into the molecular mechanism of in-
sulin action, the molecular mechanisms of
insulin resistance in human disease, and the
molecular pathophysiology of obesity. He
was one of the first to demonstrate that diet-
induced obesity in rodents is associated with
increased leptin expression and leptin re-
sistance, and that short-term starvation is as-
sociated with decreased leptin expression
and blood levels. His proposal that leptin
level serves as a switch from the fed to the
starved state has fundamentally shaped dis-
course in the field.
Flier has authored more than 200 schol-
arly papers and reviews and has held many
editorial positions, including Associate Edi-
tor of the Journal of Clinical Investigation,
and has served on the Editorial Boards of
Molecular Endocrinology, the Journal of
Clinical  Endocrinology  and  Metabolism,
and the American Journal of Medicine. He
served on the Board of Consulting Editors
of Science Magazine.
An elected member of the Institute of
Medicine  and  a  fellow  of  the American
Academy of Arts and Sciences, Flier’s hon-
ors also include the Eli Lilly Award of the
American Diabetes Association, the Berson
Lecture of the American Physiological So-
ciety, and an Honorary Doctorate from the
University of Athens. He delivered the 2003
Edwin B. Astwood Lecture Award from the
Endocrine Society and the Banting Lecture
of the American Diabetes Association, its
highest scientific honor. In 2010, Flier was
awarded an Honorary Doctor of Science De-
gree from the University of Edinburgh and
last year was awarded the 2011 Rolf Luft
Award  for  Metabolic  Research  by  the
Karolinska Institute in Stockholm, Sweden.
We are delighted and honored that he
delivered the 25th Lee E. Farr Lecture, and
his doing so is a testament to how meaning-
ful medical student research is to him.
Lee e. Farr Lecture
It is a distinct pleasure and honor to be
asked to give the Farr lecture, which has a
tradition of excellent speakers and is espe-
cially meaningful for its focus on medical
students’ research. My own research career
began when I was a medical student, and the
state of medical student research at HMS,
the school that I now lead, is something to
which  I  have  given  much  attention.  Re-
search is an aspect of medical education that
has been prominent at Yale for more than a
century. Harvard has always had many stu-
dents who do research, but as of this past
year, it is now a requirement for every en-
tering student to complete a scholarly proj-
ect, and this is an exciting initiative for the
school. 
This lecture will not focus in great de-
tail on the most recent work in my labora-
tory. Rather, my goal is to use some research
vignettes to illustrate aspects of my own ap-
proach to research over the years. I will
begin with the start of my own research dur-
ing medical school, how I continued this at
the NIH and then through a long career on
the HMS faculty at Beth Israel and then
BIDMC. I won’t speak much about being
the dean of HMS, but I will speak about
family and the bigger picture of “what it’s
all about.”
I entered the Mount Sinai School of
Medicine in 1968, in the first entering class
of the school. I was one of 36 entering stu-
dents. One of the reasons I decided to go to
Mount Sinai was that I thought being part of
this new school would be an adventure. I
406 Flier: Lee E. Farr lecturealso was impressed with the people named
as chairs of the major departments. As it
turned out, working with two of them in par-
ticular influenced me greatly. 
The chair of Biochemistry, P.G. Kat-
soyannis, led a group that was the first to
synthesize insulin through peptide synthesis
and then show it to be biologically active.
He and his colleagues made an enormous
number of insulin analogues with varying
properties  that  represented  an  important
body of work. I got to know him, and I be-
came interested in insulin during my first
few months at Mount Sinai.
The  chairman  of  Medicine  was
Solomon Berson. He became my personal
hero. He and his research partner, Rosalyn
Yalow, developed the technique of radioim-
munoassay,  and  though  he  unfortunately
died prematurely during my senior year of
medical school, Dr. Yalow went on to win
the Nobel Prize in 1977 for their joint dis-
covery, which had many practical implica-
tions, notably providing the first ability to
quantitate levels of  insulin, growth hor-
mone,  and  many  other  molecules.  So  I
worked with the person who first synthe-
sized insulin and the person who first meas-
ured it. I was clearly destined for a career
studying insulin.
I had other mentors. Dr. Kurt Hirschhorn
was an immunologist and the head of genet-
ics, and I spent most afternoons working in
his lab and authored my first paper with him.
He thought that I might go into immunology,
but I turned to endocrinology instead. The
head  of  endocrinology  was  Dr.  Dorothy
Krieger, and she was also a very important
mentor to me. She came back to the field after
having taken time away to raise children, and
she became one of the leaders in understand-
ing ACTH and proopiomelanocortin. She was
also a mentor to my wife, who was about four
years my junior in medical school.
As you can see, I had some great men-
tors at Mount Sinai, and they fostered in me
a desire to become either an endocrinologist
or an immunologist or some fusion of the
two. Shortly before he died, Dr. Berson rec-
ommended that I work with Dr. Jesse Roth,
the head of the diabetes branch at NIH who
had been Dr. Berson’s first student. At that
time, the Roth group was leading the world
in the identification and characterization of
cell surface receptors. At that time, the struc-
ture of such receptors was unknown, either
biochemically or genetically. Were they on
the membrane? Were they inside the cell?
What kind of molecules were they? How did
they generate signals? Jesse Roth’s group
had terrific science and many smart people,
and the atmosphere was quite electric. 
I was very fortunate in my research at
NIH, but during my first 6 months of re-
search, literally nothing worked. I had begun
to think that I would leave for some further
clinical training when I had one opportunity
to pursue a good idea, and everything just
sort of fell into place. A few months later,
that idea evolved in a paper in the journal
Science [1] in which we showed that some
patients with extreme insulin resistance had
autoantibodies against their insulin receptor.
The paper also showed for the first time that
the receptor we identified with this antibody
was truly critical for insulin’s action. We
were able to show that the patient’s own
cells ― removed and studied ex vivo ― had
reduced insulin binding, and we could re-
produce this by exposing normal cells to
serum  and  eventually  to  purified  im-
munoglobulin. I also thought for one intense
weekend  that  perhaps  similar  antibodies
might be the cause of type II diabetes. So I
located serum from patients with type II di-
abetes to test, but alas, they did not seem to
have these pathogenic antibodies to explain
the insulin resistance that was present.
But what was truly fascinating was an-
other group of patients that had a very sim-
ilar clinical syndrome, but they did not have
these antibodies. Many of these patients sub-
sequently proved to have mutations in the
insulin receptor gene. That said, this was the
paper that got me started, and once I had
made this observation, I said, “This is what
I am going to do for the rest of my life.” And
then the question was: “Where would I do
it?”
I had the chance to choose possible fac-
ulty positions at Beth Israel in Boston, Co-
lumbia,  and  Yale,  all  of  which  were
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place in the field of diabetes. The person
who recruited me to Beth Israel Hospital,
more than anyone else, was Franklin Ep-
stein. Some people in this audience knew
him exceptionally well [2,3]. He was a won-
derful person, a leading nephrologist, and a
great physician, famous among other things
for his Saturday rounds in which he would
round with an intern and a student. No one
who ever saw him in that context would ever
forget how he conducted these rounds.
In my time on the HMS faculty, I pur-
sued a variety of research directions. I grad-
ually added academic administration and
leadership roles to my responsibilities.
The theme of this lecture is to say a few
things about the concept of hormone resist-
ance, because at this point, I am trying to un-
derstand why it is that I kept on coming back
to this subject in my work. The simplest an-
swer is, “Because it exists!” It seems to be,
surprisingly, the key to the pathophysiology
of many diseases, including diabetes and obe-
sity, and by studying insulin resistance and
other forms of resistance, we have identified
key facts regarding hormone action, physiol-
ogy, and pathophysiology that might not have
otherwise been discovered. I’ve studied three
different molecules related to resistance. They
are insulin, leptin, and FGF21.
In the area of insulin, my research began
with rare human syndromes of extreme in-
sulin resistance, as I just discussed. These
disorders were so-called “experiments of na-
ture,” and they were both immune and ge-
netic. I also worked on common syndromes
including obesity and non-insulin-dependent
diabetes mellitus (NIDDM).
When leptin was discovered, we were
interested in aspects of leptin biology in rare
mouse syndromes and common syndromes.
Most recently, I’ve done some work with my
wife, Terry (Eleftheria Maratos-Flier), on
FGF21.
Insulin
After that paper in Science [1], we pub-
lished a paper in the New England Journal
of  Medicine describing  the  clinical  syn-
dromes of insulin resistance with the skin le-
sion, acanthosis nigricans, which is a cuta-
neous  marker  for  this  severe  resistance.
There were three patients whom we referred
to as “type B” patients who had receptor au-
toantibodies, and there were three other pa-
tients who did not have them. So we learned
that there were two new syndromes [4].
The  immune  syndrome  provided  the
best evidence that this receptor was truly the
key receptor for insulin action, and then it
provided, for a period a years, a unique tool.
Using these antibodies, we studied the re-
ceptor, explored aspects of the mechanism of
action, undertook partial purification of the
receptor, and used them to develop an im-
munoassay for the receptor. We also showed
that monovalent antibodies were antagonists
and that bivalent antibodies were agonists,
and we did that early on in the field while
that common principle of receptor dimeriza-
tion and crosslinking was still unknown.
When I came to Boston in 1978, among
the things that I decided to do was to gather
the patients who did not have these autoan-
tibodies, suspecting they would be the basis
for a new line of discovery. I began to collect
these  patients  clinically  and  created  cell
lines from them. It was not until 1985 that
the insulin receptor was cloned ― consid-
ered a major breakthrough at the time ― and
it made the cover of Nature [5]. With that in-
formation, we looked at the patients we had
and discovered insulin receptor mutations in
several.  We  characterized  them,  and  for
about 5 to 7 years, that was a significant por-
tion of my work.
At  various  points,  I  thought  that  we
would learn far more about the nature of in-
sulin signaling by working with these differ-
ent mutants, but it just did not work out that
way. We learned a great deal, but we reached
a point where “the well ran dry.” There were
few other molecules related to insulin sig-
naling that we could study along with the re-
ceptor. So where do we stand 23 years after
the discovery of the genetic syndromes and
36 years after the autoantibodies?
We know that a syndrome of severe in-
herited insulin resistance with acanthosis
nigricans (type A) exists. It turns out, in ret-
rospect, that only about 15 percent have
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efforts to find the molecular explanation
now with deep sequencing. Almost all of
those identified mutations are of the insulin
receptor. The insulin receptor substrates
have not been established as a cause. There
a couple of extremely rare, single case fam-
ilies, in which resistance appears to be due
to dominant negative Akt2 [6], but we still
don’t  have  an  adequate  explanation  for
most patients with severe inherited insulin
resistance, and I never would have pre-
dicted that to be true so many years after
this research began.  
And what about the case of insulin re-
sistance in type II diabetes, an extremely im-
portant  and  prevalent  disease?  Insulin
resistance is common, develops early in the
course of the disorder, and appears to be
strongly influenced by genetics. Amazingly,
the genetic etiology of insulin resistance in
type II diabetes remains largely unknown.
After millions spent on sequencing of can-
didate genes and on genome-wide associa-
tion  studies,  the  canonical  signaling
pathways seem to be exonerated, and few, I
believe, predicted that outcome. So what are
the causative genes? We don’t know. What
about leptin?
Leptin
I had been interested, even as a fellow
at the NIH, in the ob/ob mouse model. I
made a number of abortive attempts to do
research related to them, but I decided that
someday I would work on these mice be-
cause there had to be something profoundly
important to explain this recessive obesity.
Then in December 1994, a paper by Jeff
Friedman [7], who has given an earlier Farr
Lecture and is a friend of mine, reported on
the cloning of the ob gene, demonstrating
that it encoded a protein mainly expressed
in fat. This protein is essentially absent in
the ob/ob mouse due to a nonsense mutation.
This discovery changed everyone’s thinking
about the field of energy balance.
As an aside, 7 or 8 years before that
paper, I worked on a molecule called adipsin
in collaboration with Bruce Spiegelman, and
for a while we were convinced that adipsin
could be the missing fat-cell-secreted protein
whose  absence  could  cause  obesity.  We
worked very hard to see if that could possibly
be true. A few months after that, we published
two back-to-back papers in Science. The one
that reported my portion of the work showed
that there was severely impaired adipsin ex-
pression in genetic and acquired obesity [8].
We then spent considerable time working with
a company that we co-founded to give re-
combinant adipsin to ob/ob mice to see if we
could cure obesity. The bottom line was that
we did not have any effect on obesity, and to
this day, we do not know what exactly is going
on with this adipocyte-secreted protein, which
we now know as “complement factor D.” It
still remains an open question. The only last-
ing positive from that work is a tremendous
collaboration and friendship with Bruce that
lasts to this day. I also became psychologically
prepared for the discovery of leptin when it
was discovered by Jeff Friedman. 
In 1995, leptin was known in the field
as an anti-obesity hormone. The physiolog-
ical feedback loop was thought to be that as
you get fatter, your fat cells enlarge and lep-
tin production goes up ― which it does ―
and then this somehow acts on the brain.
There was evidence that it had a very pow-
erful action on the brain, and the conse-
quence of acting on the brain would be to
reduce food intake and increase energy ex-
penditure, causing weight loss in an elegant
feedback loop. That’s the way it was imag-
ined to work.
In fact, that construct was consistent,
not only with the initial mouse data, but with
exciting human data. The first ob/ob human
treated with leptin showed a dramatic effect
of leptin therapy [9]. Within 24 hours of re-
ceiving leptin, the individual treated was eat-
ing a normal amount of food and remarkable
weight loss followed. These studies were
conducted by Sadaf Farooqi and Stephen
O’Rahilly. Steve had been a post doc in my
lab at Beth Israel working on the genetics of
insulin resistance a few years earlier.
My lab devised a way to quantitate lep-
tin, and we measured it in fat and lean mice,
and we showed that there was an extremely
clear  positive  relationship  between  total
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greater at any given body fat in female mice
than in male mice, a result that holds true in
every other subsequent study. We wrote a
paper that claimed that leptin levels reflect
body lipid content in mice and that this pro-
vided evidence for diet-induced resistance
to leptin action; this is the earliest of 3,000
articles on PubMed if one searches “leptin
resistance” [10]. On the human side ― in
the New England Journal of Medicine paper
that followed ― you could also see a posi-
tive relationship between leptin levels in
blood  and  body  fat,  and  once  again  it
seemed that my research was gravitating to-
ward the phenomenon of resistance. 
This led to one of the great “ah-ha” mo-
ments of my career. In 1995, I was teaching
Harvard medical students in their basic me-
tabolism course. One of the things that I
taught was the physiology of insulin, and it
having two roles. When you eat, it is impor-
tant that insulin levels go up to prevent hy-
perglycemia, and when you are not eating,
it’s extremely critical that insulin levels go
down. If they don’t go down, you will die of
hypoglycemia. So the fall in insulin during
food restriction is as important ― if not
more important ― than the rise. That is
when I got to thinking that perhaps the same
concept might be true for leptin. Perhaps
falling leptin was a starvation signal. The
idea would be that as you starve, the leptin
levels go down ― which we showed to be
the case ― and that would be a signal to the
brain to increase food intake and decrease
energy  expenditure.  Falling  leptin  might
also be an endocrine regulator, because we
know that when you starve, reproduction is
suppressed and various other endocrine axes
are suppressed.
So we did an experiment to test that hy-
pothesis. I had a wonderful endocrine fellow
at the time, Rex Ahima, who had trained in
neuroendocrinology before he came to our
endocrine program. I had tried to sell this
project to three different fellows before Rex.
They had all been nice, smart people, but
none of them were motivated to take on this
experiment. When I mentioned this project
to Rex Ahima, he was immediately excited
and had excellent ideas about how to ap-
proach the critical experiment. So we took
some normal mice and we fasted them, with
or without replacing leptin. We found that
fasting alone caused a long delay in estrus
cycling, but when we gave leptin during the
fast, that delay of estrus did not occur. And
then we also did studies with thyroid and
other endocrine axes, and, though not as dra-
matic, there was a similar story, with leptin
limiting the effect. And the last line of our
paper was, “Given the high prevalence of
apparent leptin resistance in obese rodents
and humans, the physiologic response to de-
creasing leptin concentration with starvation
may be the dominant role of this hormone.”
When we submitted this paper to Na-
ture originally, it was rejected on the basis
of comments from two reviewers. Ironically,
the first reviewer said that “it could not pos-
sibly  be  true,”  and  the  other  one  said,
“everyone already knows that it’s true.” In
the end, the paper was published, and it has
been cited more than any I’ve written, about
2,500 at the moment [11]. I’m also happy to
say that Rex was recently made a full pro-
fessor of medicine at Penn, and he is an out-
standing investigator of whom I am very
proud.  
We were interested in discovering the
mechanisms for leptin resistance. We gave
leptin to mice who were either on a typical
low-fat diet or on a high-fat diet. We took
out the hypothalamus after leptin adminis-
tration and looked to see if leptin was acti-
vating  signals  in  the  hypothalamus  of
animals with the high fat diet, and it was not.
That indicated that there was leptin resist-
ance at the level of signaling caused by high
fat diets in these obese mice. But what was
the molecular basis of this leptin resistance?
There was an issue of Nature in which three
papers came out describing the suppressors
of  cytokine-signaling-family  of  proteins
[12]. Since leptin is a member of the broad
cytokine family of proteins, we made probes
for all the SOCS-family proteins that we
knew of at the time and found that only one,
SOCS3, was activated by leptin, and it was
activated precisely in the medial basal hy-
pothalamus, where leptin has important ac-
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those cells that have leptin receptors that
SOCS3  mRNA  is  induced,  and  then  we
showed that if you co-express SOCS3 with
a leptin-responsive system that you block
leptin signaling. So now we had a molecule
that was induced by leptin, and that would
cause leptin resistance, and we spent 5 years
working on that, trying to understand it. The
key question was, would SOCS3 deficiency
actually protect against obesity?
We were able to rapidly obtain some
SOCS3 knockout mice. In the homozygous
form, SOCS deficiency is embryonic lethal,
and so we studied heterozygous knockout
mice and we found what we were hoping to
find, that is, at a very low dose of leptin the
mice with only one SOCS3 allele had a bet-
ter response to leptin administration than the
wild type mice and these haplo-insufficient
mice also had a greater loss of triglyceride
mass in response to leptin. In further stud-
ies, we asked, “Are SOCS3 haplo-insuffi-
cient mouse protected against obesity?” And
the answer was yes, they are. So, whereas a
normal mouse on a high-fat, high-sugar diet
will gain weight, the SOCS3 haplo-insuffi-
cient mouse gained less weight. They also
did not increase food intake or show a rise in
glucose as did the wild type mouse.
And then even more interestingly, it
turned out that SOCS3 is also an antagonist
of insulin signaling. So SOCS3 is actually a
very good candidate to be one of the major
mediators of both leptin and insulin resist-
ance. The problem with leptin resistance
being localized primarily to the brain is that
we cannot readily sample the hypothalamus
of humans. So we cannot readily prove that
this mechanism occurs in the medial basal
hypothalamus of humans.
So leptin resistance characterizes typi-
cal obesity in humans. It most often is ac-
quired and rarely is genetic. It’s selective, so
that even within the central nervous system,
leptin’s reproductive signal remains largely
intact while the effect on body weight is di-
minished. This may be evolutionarily ad-
vantageous in that leptin’s primary role may
be  in  the  transition  from  the  fed  to  the
starved state as leptin levels decrease, while
leptin also confers limited protection against
excessive energy storage as leptin levels
rise. That’s the hypothesis that I am fond of,
but if true, it would limit the therapeutic re-
sponse to leptin, and as you probably know,
there has been little success in leptin’s ther-
apeutic application despite the efforts of sev-
eral companies.
To summarize, the genetic causes of lep-
tin resistance are limited to rare leptin recep-
tor mutations that cause severe congenital
obesity, and I believe that identifying the mo-
lecular mechanisms responsible for leptin re-
sistance in typical obesity should be a high
priority in obesity and diabetes research.
FGF21
Though this may seem an odd segue, I
sense there may be some working couples
here who may benefit from this, so I would
like to answer the question of what it is like
to actually collaborate with your wife as a
scientist for 34 years. Terry and I had always
been advised that we should never work to-
gether, but we worked together on many dif-
ferent topics and have authored 29 papers
together on a variety of topics, and we have
actually found that our work has been syn-
ergistic with each of us making significant
contributions. As my administrative respon-
sibilities have increased, my primary scien-
tific contribution has decreased, and I will
close this lecture with some remarks about
the work related to FGF21 that has been pre-
dominantly hers.
FGF21 is a new and exciting metabolic
hormone. It is a member of the FGF gene
family; it is dominantly, but not exclusively,
expressed in the liver. It acts through a sub-
set of FGF receptors. It requires a co-recep-
tor, beta klotho.
FGF21 gained scientific attention after
researchers at Eli Lilly published a paper
showing both in vitro and in vivo stimulation
by FGF21 of glucose uptake into fat cells by
inducing glucose transporter synthesis [13].
FGF21 is an interesting candidate for the
treatment of non-insulin-dependent diabetes
mellitus (NIDDM).
We  entered  the  field  as  a  result  of
Terry’s studies that aimed to understand the
411 Flier: Lee E. Farr lecturemolecular physiology of the very low car-
bohydrate, high-fat, so called “ketogenic”
diet that produces weight loss in a manner
that she felt required molecular explanation.
We all know about the Atkins diet, much de-
bated and much discussed, and we know that
it works, but no one had done an Atkins-like
mouse model to try to understand energy
balance and the molecular basis of the diet,
so that’s what Terry did with four groups of
normal lab mice.
One group was fed regular chow, one
the typical high-fat, high-sucrose diet, and
one the ketogenic diet, which is a specially
made diet that has high-fat and low-carbo-
hydrate. The fourth group was fed normal
chow but was calorically restricted such that
it would lose the same amount of weight as
the group fed the ketogenic diet. The first
three groups, ketogenic diet group included,
ate exactly the same number of calories; the
calorie-restricted group ate 30 percent fewer
calories [14].
She found that though the mice on the ke-
togenic diet ate as many calories as the mice
eating a high-fat diet or regular chow, they
dramatically lost weight while appearing to be
otherwise healthy. They lost as much weight
as mice eating normal chow but 30 percent
fewer calories. This was a striking observa-
tion and indicated that the consumption of the
ketogenic diet induces a unique metabolic
state and weight loss with unchanged caloric
intake, and this has now been repeated three or
four times and many physiological correlates
have been investigated and published. These
ketogenic diet mice have very low insulin lev-
els, ketosis, increased energy expenditure, in-
creased insulin sensitivity, and a mild fatty
liver, but not a fatty liver of the variety that
would be worrisome.
So then the question was: What is the
molecular explanation? We did not feel that
there was an adequate explanation based on
changes in the levels of known hormones.
So we performed transcriptional analysis by
gene arrays on the mildly fatty liver, and we
found that changes in the levels of one gene
were striking. That gene was FGF21.
We found that FGF21 expression was
markedly and selectively induced in the liver
by  ketogenic  diets. After  we  found  that
FGF21 expression in the liver was physio-
logically regulated by simple starvation, we
made an adenoviral anti-sense to inject into
the circulation and knock down FGF21 in
liver, and when we put those mice on keto-
genic diet, we saw a massive increase of fat
in the liver. FGF21 appeared to be necessary
for the adaptive increased burning of fat.
Then we were fortunate to collaborate
with Eli Lilly, which 3 years earlier had
made FGF21 knockout mice. As we knew,
if we put the wild-type mice on a ketogenic
diet, they lost weight. If we put the FGF21
knockout mice on ketogenic diet, however,
they actually gained weight. They also had
increased food intake, increased body fat,
and all the hallmarks of hepatic steatosis. In
this way, we had found that FGF21 is an es-
sential molecular mediator of the weight loss
associated with a ketogenic diet. This was
quite exciting to us.
We  have  gone  on  more  recently  to
human studies and found that people with
non-alcoholic fatty liver disease (NAFLD)
have higher levels of FGF21 in their blood.
To recapitulate, we now know that FGF21
has a role in lipid metabolism, and this arose
from studies of the ketogenic diet in the
manner that I have described. Suppression
of FGF21 in the liver using adenovirus or
systemically through gene knockouts has
major phenotypes, as I’ve described. In re-
cent work, we show that obese humans with
NAFLD have paradoxically increased ex-
pression levels of FGF21. One would think,
given the studies of FGF21 knockout mice
above, that high FGF21 levels should be
protective against steatosis. These patients
have high levels of FGF21, but they also
have fatty liver disease. This new finding
brings us back again to a theme that has been
recurring throughout my career: Is there also
resistance to FGF21? The answer seems to
be, yes, indeed these patients are FGF21 re-
sistant [15]. 
The study of this novel hepatic hormone
is very exciting. We know that its expression
in the liver is regulated by the composition
and volume of the diet, and it has actions re-
lated to lipid oxidation and adipocyte glucose
412 Flier: Lee E. Farr lectureuptake. There are many other issues currently
under investigation in our lab and elsewhere,
and now it seems that FGF21 also has an ac-
tion in the brain. It is also a regulator of
brown adipose tissue thermogenesis. Terry
and Bruce Spiegelman have just published a
paper showing that FGF21 induces brown fat
activation in white fat depots and promotes
weight  loss  [16].  There  also  seem  to  be
mechanisms for FGF21 action to limit he-
patic lipid accumulation and toxicity, fibro-
sis, and inflammation, and we are trying to
understand how this occurs, and we are try-
ing to understand the mechanism for FGF21
resistance. The current state is: FGF21 action
and resistance may be important factors in
the pathophysiology of obesity, Type II dia-
betes, and NAFLD. And it is a potential
novel therapy for diabetes and NAFLD, and
this is being explored by several pharmaceu-
tical companies.
Hormone Resistance, in Summary
Hormone resistance seems to be at the
core of the pathophysiology of obesity and
Type  II  diabetes,  and  insulin,  leptin,  and
FGF21 are certainly involved. Well-delin-
eated genetic causes exist, at least for insulin
and leptin resistance, but these are rare, and
the genetic and molecular etiology in the vast
majority of patients with common syndromes
remains uncertain despite much effort. I find
this very disappointing given the advances in
fundamental understanding in the field, espe-
cially for insulin signaling over the past 30
years. We have illuminated the black box
such that we know an extraordinary amount
about insulin signaling; we know dozens of
molecules that are modulated up and down
and are phosphorylated and dephosphory-
lated, but we still don’t know the genetic
cause for insulin resistance in Type II dia-
betes. This does suggest, however, that major
breakthroughs remain to be made, so I would
counsel investigators to remain in this ex-
tremely important field. This disease is as im-
portant as it ever was, and many of the big
questions have yet to be answered.
Allow me to end with a few reflections.
The first: Medicine is and will remain an ex-
traordinary profession. Research is under as-
sault, as its funding sources are being threat-
ened, but I do believe that it is still a won-
derful career choice. Second, I would say
that for anyone wishing to do research over
the course of a career, you should take ad-
vantage of the diversity ― and the surprises
― that will emerge over a lifetime and ca-
reer. It may seem at the beginning that it will
be a simple path. One may think, “I'm going
to do this, and then I'm going to keep doing
it,” but it almost never works out that way. I
know people, friends of mine, who have
been extremely successful in that way, they
just go deeper and deeper and deeper on the
same problem, and that is great if you can
do it. But I also know many people who
have moved from one important problem to
another and even from one field to another
and they can also be very, very successful.
More often than not, there will be surprises
rather than a straightforward path.
Third, whatever your area ― whether it
is biomedical bench science, or social sci-
ence, or policy ― remain alert for ideas,
connections, and opportunities that suggest a
new direction. They are out there, but you
should expect some negative response be-
cause you will always get some negative re-
sponses to your best ideas, and our job is to
not be discouraged inappropriately.
Fourth, it is really important to have
mentors and role models, and I think your
program here at Yale has been built upon that
thesis for over a hundred years. The only
thing that I would counsel is this: Do not
seek to imitate your mentors. I know people
who walk like, talk like, and have body tics
like their mentors. Body tics are not usually
a good thing to emulate. Take elements, but
do not take the whole package. And then the
final point ― though it might sound a little
sappy ― in the end, over a lifetime, happi-
ness is the key, and this may not always cor-
relate with professional success. You may be
in many situations where you will be needing
to make choices that balance your personal
happiness and that of your family with your
profession, and there are people who make
the wrong decisions every day when they are
confronted by these choices, but striking the
proper balance is what life is all about. 
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